Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.60 |
| ▸ | ITGB3 | P05106 | 17/20 | 0.60 |
| ▸ | ITGB6 | P18564 | 8/20 | 0.47 |
| ▸ | ITGB8 | P26012 | 7/20 | 0.47 |
| ▸ | ITGB5 | P18084 | 6/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6431343 | 1.00 | ITGAV (0.60) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL5304862 | 0.98 | ITGAV (0.63) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL5304869 | 0.98 | ITGAV (0.63) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL5298439 | 0.90 | ITGAV (0.61) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL5298453 | 0.90 | ITGAV (0.61) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL5305490 | 0.89 | ITGAV (0.72) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL5305487 | 0.89 | ITGAV (0.72) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL27563545 | 0.87 | ITGAV (0.55) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL6741101 | 0.84 | ITGAV (0.67) | ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL6741108 | 0.84 | ITGAV (0.67) | ITGAVITGB3ITGB6ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101593-A1 | Phosphoric acid salt of an integrin receptor antagonist | MEISSNER ROBERT S (US) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101593-A1 | Phosphoric acid salt of an integrin receptor antagonist | ITGA5, ITGAL, ITGA2 | ITGAV 12/4885ITGB3 5/4885ITGB6 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.